Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) – Oppenheimer Holdings decreased their Q3 2018 EPS estimates for shares of Vanda Pharmaceuticals in a report issued on Sunday. Oppenheimer Holdings analyst D. Archila now anticipates that the biopharmaceutical company will earn $0.00 per share for the quarter, down from their previous forecast of $0.01. Oppenheimer Holdings currently has a “Buy” rating and a $25.00 target price on the stock. Oppenheimer Holdings also issued estimates for Vanda Pharmaceuticals’ Q4 2018 earnings at $0.04 EPS.
VNDA has been the subject of several other research reports. Zacks Investment Research lowered shares of Vanda Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, October 26th. ValuEngine cut shares of Vanda Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Thursday, October 26th. Jefferies Group LLC reaffirmed a “buy” rating and issued a $21.00 target price on shares of Vanda Pharmaceuticals in a report on Tuesday, August 29th. Finally, Piper Jaffray Companies set a $26.00 target price on shares of Vanda Pharmaceuticals and gave the company a “buy” rating in a report on Thursday, October 19th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and five have issued a buy rating to the company. Vanda Pharmaceuticals has an average rating of “Buy” and an average target price of $21.50.
ILLEGAL ACTIVITY NOTICE: This piece of content was published by Stock Observer and is the sole property of of Stock Observer. If you are accessing this piece of content on another publication, it was illegally copied and reposted in violation of United States and international copyright laws. The correct version of this piece of content can be read at https://www.thestockobserver.com/2017/11/14/vanda-pharmaceuticals-inc-vnda-to-post-q3-2018-earnings-of-0-00-per-share-oppenheimer-holdings-forecasts.html.
Vanda Pharmaceuticals (NASDAQ VNDA) traded up $0.08 during midday trading on Tuesday, hitting $13.03. 52,441 shares of the stock traded hands, compared to its average volume of 559,185. Vanda Pharmaceuticals has a twelve month low of $11.90 and a twelve month high of $18.99.
Vanda Pharmaceuticals (NASDAQ:VNDA) last posted its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported ($0.10) EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.10). Vanda Pharmaceuticals had a negative net margin of 9.01% and a negative return on equity of 10.99%. The business had revenue of $41.30 million during the quarter, compared to analyst estimates of $43.90 million. During the same quarter last year, the firm posted ($0.01) earnings per share. The business’s revenue for the quarter was up 7.3% compared to the same quarter last year.
A number of hedge funds have recently added to or reduced their stakes in VNDA. American International Group Inc. raised its holdings in Vanda Pharmaceuticals by 7.1% during the first quarter. American International Group Inc. now owns 22,563 shares of the biopharmaceutical company’s stock worth $316,000 after purchasing an additional 1,491 shares in the last quarter. FMR LLC raised its holdings in Vanda Pharmaceuticals by 60.7% during the first quarter. FMR LLC now owns 1,601,171 shares of the biopharmaceutical company’s stock worth $22,416,000 after purchasing an additional 604,900 shares in the last quarter. Teachers Advisors LLC raised its holdings in Vanda Pharmaceuticals by 1.0% during the first quarter. Teachers Advisors LLC now owns 535,861 shares of the biopharmaceutical company’s stock worth $7,502,000 after purchasing an additional 5,180 shares in the last quarter. TIAA CREF Investment Management LLC raised its holdings in Vanda Pharmaceuticals by 5.1% during the first quarter. TIAA CREF Investment Management LLC now owns 408,952 shares of the biopharmaceutical company’s stock worth $5,725,000 after purchasing an additional 19,674 shares in the last quarter. Finally, Vanguard Group Inc. raised its holdings in Vanda Pharmaceuticals by 26.4% during the first quarter. Vanguard Group Inc. now owns 2,494,347 shares of the biopharmaceutical company’s stock worth $34,920,000 after purchasing an additional 521,669 shares in the last quarter. 87.28% of the stock is currently owned by institutional investors.
Vanda Pharmaceuticals Company Profile
Vanda Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to address unmet medical needs. Its product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. It offers HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24).
Receive News & Ratings for Vanda Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.